Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolcapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT known ✓ | P21964 | 1/20 | 1.00 |
| ▸ | TTR | P02766 | 8/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | KLF10 | Q13118 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolcapone SCHEMBL5496772 | 1.00 | TTR (1.00) | TTRGPR35ABCC3ABCC4NR1I2 | |
| Tolcapone SCHEMBL29360457 | 1.00 | TTR (1.00) | TTRGPR35ABCC3ABCC4NR1I2 | |
| Tolcapone SCHEMBL28597786 | 0.98 | TTR (0.97) | TTRGPR35ABCC3ABCC4NR1I2 | |
| Tolcapone SCHEMBL21438679 | 0.94 | TTR (0.89) | TTRGPR35ABCC3ABCC4NR1I2 | |
| Tolcapone SCHEMBL29004414 | 0.93 | TTR (0.87) | TTRGPR35ABCC3ABCC4NR1I2 | |
| SCHEMBL18805094 | 0.88 | TTR (0.78) | TTRGPR35ABCC3ABCC4NR1I2 | |
| SCHEMBL7363677 | 0.88 | TTR (0.78) | TTRGPR35ABCC3ABCC4NR1I2 | |
| SCHEMBL7368380 | 0.87 | TTR (0.81) | TTRGPR35ABCC3ABCC4NR1I2 | |
| Tolcapone SCHEMBL4391775 | 0.86 | TTR (0.73) | TTRGPR35ABCC3ABCC4NR1I2 | |
| Bromide SCHEMBL7365276 | 0.85 | TTR (0.78) | TTRGPR35ABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14993 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746864-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION | Keto Innovations, LLC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026106939-A1 | IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260131140-A1 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIV (US) | 2026-05-14 | — | — | US | claimed |
| US-20260124146-A1 | MODIFIED RELEASE TOLCAPONE FORMULATIONS | CORINO THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| WO-2026090582-A1 | COMPOSITIONS CONTAINING A NON-XANTHINE CNS STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | AXCESS GLOBAL SCIENCES, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4712954-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | Keto Innovations, LLC (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-0952820-A1 | PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-03 | — | — | EP | claimed |
| CN-1233169-A | Preparation process of powdery preparation | HOFFMANN LA ROCHE (CH) | 1999-10-27 | — | — | CN | claimed |
| EP-0855379-A1 | Methods for the preparation of benzophenones derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-29 | — | — | EP | claimed |
| WO-1998031355-A2 | PHARMACEUTICAL COMPOSITION COMPRISING N-PROPYLNORAPOMORPHINE AND CATHECOL-O-METHYL-TRANSFERASE INHIBITOR FOR TREATING PARKINSON'S DISEASE | BRITANNIA PHARMACEUTICALS LIMITED (GB) | 1998-07-23 | — | — | WO | claimed |
| WO-1998016204-A1 | PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-23 | — | — | WO | claimed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | claimed |
| US-5476875-A | Catechol derivatives | HOFFMAN-LA ROCHE INC. (US) | 1995-12-19 | — | — | US | claimed |
| US-5236952-A | Inhibit the enzyme catechol-O-methyltransferase; for treatment of Parkinson's disease administered with L-dopa | HOFFMANN-LA ROCHE INC. (US) | 1993-08-17 | — | — | US | claimed |
| EP-0237929-B1 | 3,5-DISUBSTITUTED PYROCATECHOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | claimed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | claimed |